Drs. Andrew Pekosz and Sabra Klein of JHCEIRS are part of a collaboration at Johns Hopkins University that will evaluate the effectiveness of convalescent blood plasma therapy for COVID-19. The research team received $35 million in funding from the U.S. Department of Defense to support randomized clinical trials at twenty medical sites across the country. Over one thousand participants will be enrolled across two groups—those that have been exposed to SARS-CoV-2 and those in early stages of the illness—then monitored and tested over a four-week period for symptom development and disease severity. Researchers will utilize these clinical data to answer questions on long-term immunity, such as whether the therapy can improve disease outcomes or prevent infection all together. The team hopes these efforts can demonstrate the benefits of convalescent plasma therapy and its application as a low-cost, outpatient option to prevent and treat COVID-19 while vaccine development continues. You can find more information as well as a video featuring the investigators leading the trials here.